潜在收购交易 - 强生公司据称正在洽谈收购Protagonist Therapeutics公司，但交易尚未最终确定，条款也未敲定 [1] - 若交易完成，将强化强生公司的免疫学业务，并获得实验性疗法rusfertide的权益 [3] Protagonist Therapeutics公司概况 - Protagonist Therapeutics公司股价年初至今已上涨约132%，自2016年首次公开募股以来累计涨幅超过450% [1][5] - 公司股价在报道发布当日上涨34.04%，至89.86美元，创下52周新高 [7] 现有合作与战略契合度 - 两家公司已就开发针对斑块状银屑病和溃疡性结肠炎的口服疗法存在合作，强生拥有该疗法的独家商业化权利并持有Protagonist约4%的股份 [2][3] - 收购Protagonist符合强生通过新产品发布和针对性收购来应对其畅销免疫药物Stelara所面临竞争压力的战略 [6] - Protagonist的研发管线产品有望补充强生不断扩大的免疫和肿瘤产品组合 [4]

Key TakeawaysU.S. equity markets showed resilience, with the S&P 500 and Nasdaq Composite posting slight gains by Friday's close, while Chinese markets, notably the NASDAQ Golden Dragon China Index, experienced a significant 2.6% decline, marking its steepest fall since August 27th.Johnson & Johnson (JNJ) is reportedly in advanced discussions to acquire Protagonist Therapeutics (PTGX), according to the Wall Street Journal, a development that saw Protagonist shares surge.Geopolitical tensions escalated as Ch ...

Protagonist Therapeutics (NASDAQ:PTGX), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the company. Citing people familiar with the matter, the publication noted ...

Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter. ...

The two companies are already codeveloping a treatment for ulcerative colitis. ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.'s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance. 10 Best Healthcare Dividend Stocks To Buy Protagonist Therapeutics (PTGX) presents a compelling investment case following strong clinical progress and underappr ...

华尔街分析师评级变动 - B Riley Securities分析师Mayank Mamtani首次覆盖Theravance Biopharma(TBPH) 给予买入评级 目标价28美元 较周四收盘价13.70美元存在104%上行空间 [3] - Leerink Partners分析师Faisal Khurshid首次覆盖Protagonist Therapeutics(PTGX) 给予跑赢大盘评级 目标价73美元 较周四收盘价59.68美元存在22%上行空间 [3] - Barclays分析师David Strauss首次覆盖StandardAero(SARO) 给予超配评级 目标价32美元 较周四收盘价27.35美元存在17%上行空间 [3] 生物制药行业关注度 - 两家生物制药公司Theravance Biopharma和Protagonist Therapeutics同时获得机构首次覆盖并给予正面评级 [3] - Protagonist Therapeutics(PTGX)获得市场重点关注 分析师对其投资前景进行专门解读 [2]

rusfertide突破性疗法认定 - rusfertide用于真性红细胞增多症获得突破性疗法认定 这是该药物第二次获得此项认定[1] - 此前曾获得突破性疗法认定 但基于临床前研究结果被撤销[1] - 公司重新申请突破性疗法认定并获得通过 显示监管机构对药物安全性和疗效特征的认可[1] 公司研发态度 - 公司对研发保持高度谨慎态度 不将任何进展视为理所当然[2] - 坚持持续专注研发工作 始终保持警觉状态[2] - 感谢各方邀请参会 重视外部交流机会[2]

rusfertide突破性疗法认定 - rusfertide针对真性红细胞增多症获得突破性疗法认定 这是该药物第二次获得此项认定 [1] - 此前曾获得突破性疗法认定 但因临床前研究结果被撤销 [1] - 公司重新申请突破性疗法认定并获得通过 [1] 公司研发态度 - 公司对研发持谨慎态度 不认为任何成果是理所当然的 [2] - 强调研发工作具有不确定性 需要始终保持高度警惕 [2] - 感谢外界对公司的关注和邀请 [2]